Evidence map›Paper›PMID 38923117›Full record

ArticleJournal of biomedical materials research. Part B, Applied biomaterials2024

Analysis of the broad-spectrum potential of nitric oxide for antibacterial activity against clinically isolated drug-resistant bacteria.

Lori M Estes Bright, Manjyot Kaur Chug, Stephen Thompson, Megan Brooks, Elizabeth J Brisbois, Hitesh Handa

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of biomedical materials research. Part B, Applied biomaterials, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Lori M Estes BrightSchool of Chemical, Materials, and Biomedical Engineering, College of Engineering, University of Georgia, Athens, Georgia, USA.
Manjyot Kaur ChugSchool of Chemical, Materials, and Biomedical Engineering, College of Engineering, University of Georgia, Athens, Georgia, USA.
Stephen ThompsonSchool of Chemical, Materials, and Biomedical Engineering, College of Engineering, University of Georgia, Athens, Georgia, USA.
Megan BrooksSchool of Chemical, Materials, and Biomedical Engineering, College of Engineering, University of Georgia, Athens, Georgia, USA.
Elizabeth J BrisboisSchool of Chemical, Materials, and Biomedical Engineering, College of Engineering, University of Georgia, Athens, Georgia, USA.ORCID 0000-0002-9283-5448
Hitesh HandaSchool of Chemical, Materials, and Biomedical Engineering, College of Engineering, University of Georgia, Athens, Georgia, USA.ORCID 0000-0002-9369-7374

Funding

Engineering nitric oxide releasing polymer with immobilized thrombin inhibitor for blood contacting applicationsR01HL134899 · NHLBI · UNIVERSITY OF GEORGIA · PI HANDA, HITESH · 2017 to 2025
$3.0M
Heparin-free extracorporeal circulation via combined nitric oxide releasing/generating surfacesR01HL157587 · NHLBI · UNIVERSITY OF GEORGIA · PI BRISBOIS, ELIZABETH JOY · 2021 to 2024
$1.5M
Bioinspired antifouling and thromboresistant polymers for blood-contacting interfacesR01HL151473 · NHLBI · UNIVERSITY OF GEORGIA · PI BRISBOIS, ELIZABETH JOY · 2020 to 2023
$1.4M
National Institutes of Health, USA R01HL134899National Institutes of Health, USA R01HL151473National Institutes of Health, USA R01HL157587NHLBI NIH HHS R01 HL134899NHLBI NIH HHS R01 HL151473NHLBI NIH HHS R01 HL157587
6 · The paper itself

Abstract

The development of drug-resistant microorganisms is taking a heavy toll on the biomedical world. Clinical infections are costly and becoming increasingly dangerous as bacteria that once responded to standard antibiotic treatment are developing resistance mechanisms that require innovative treatment strategies. Nitric oxide (NO) is a gaseous molecule produced endogenously that has shown potent antibacterial capabilities in numerous research studies. Its multimechanistic antibacterial methods prevent the development of resistance and have shown potential as an alternative to antibiotics. However, there has yet to be a direct comparison study evaluating the antibacterial properties of NO against antibiotic susceptible and antibiotic-resistant clinically isolated bacterial strains. Herein, standardized lab and clinically isolated drug-resistant bacterial strains are compared side-by-side for growth and viability following treatment with NO released from S-nitrosoglutathione (GSNO), an NO donor molecule. Evaluation of growth kinetics revealed complete killing of E. coli lab and clinical strains at 17.5 mM GSNO, though 15 mM displayed >50% killing and significantly reduced metabolic activity, with greater dose dependence for membrane permeability. Clinical P. aeruginosa showed greater susceptibility to GSNO during growth curve studies, but metabolic activity and membrane permeability demonstrated similar effects for 12.5 mM GSNO treatment of lab and clinical strains. MRSA lab and clinical strains exhibited total killing at 17.5 mM treatment, though metabolic activity was decreased, and membrane permeation began at 12.5 mM for both strains. Lastly, both S. epidermidis strains were killed by 15 mM GSNO, with sensitivities in metabolic activity and membrane permeability at 12.5 mM GSNO. The mirrored antibacterial effects seen by the lab and clinical strains of two Gram-negative and two Gram-positive bacteria reveal the translational success of NO as an antibacterial therapy and potential alternative to standard antibiotic treatment.

Indexed as

Anti-Bacterial AgentsEscherichia coliNitric OxideDrug Resistance, BacterialHumansMicrobial Sensitivity TestsNitric Oxide DonorsPseudomonas aeruginosaS-NitrosoglutathioneAnti-Bacterial AgentsNitric OxideNitric Oxide DonorsS-Nitrosoglutathioneantibacterialclinicalinfectionnitric oxideS‐nitrosoglutathione

Identifiers

PMID38923117
PMCPMC11727359

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.